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Figure 1 Flow Diagram
The diagram depicts study patient enrollment, randomization, and coronary
imaging in the YELLOW trial, among patients with stable coronary artery disease
Abbreviations
and Acronyms
ANCOVA = analysis of
covariance
CAD = coronary artery
disease
FFR = fractional ﬂow reserve
IVUS = intravascular
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LCBI = lipid-core burden
index
LCBI4mm max = change in
lipid-core burden index at the
4-mm maximal segment
NIRS = near-infrared
spectroscopy
PCI = percutaneous coronary
intervention
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22atheroma volume has been most
commonly reported, plaque com-
position may play a crucial role in
the progression to acute coronary
syndrome (7,8) or the need for
revascularization (9). In particular,
lipid-rich ﬁbroatheromas are at
increased risk for plaque rupture
and thrombosis (10,11). Of all
plaque components, the lipid core
exhibits the highest thrombogenic
activity (12). Emerging data using
novel in vivo imaging modalities
suggest that statins might have
a greater impact on modulating
lipid content versus plaque volume
(13–16). With computed tomo-
graphy angiography and radio-
frequency or backscatter IVUS,(CAD) presenting for coronary angiography and revascularization. CRF ¼ Cardio-
vascular Research Foundation; FFR ¼ fractional ﬂow reserve; IVUS ¼ intravascular
ultrasound; MSH ¼ Mount Sinai Hospital; NIRS ¼ near-infrared spectroscopy.
Table 1 Baseline Characteristics by Randomized Group
Standard
(n ¼ 43)
Intensive
(n ¼ 44) p Value
Age, yrs 62.9  9.8 64.4  9.29 0.46
Female, % 27.9 20.5 0.42
Current tobacco use, % 9.5 20.5 0.52
Hypertension, % 95.3 90.9 0.41
Hypercholesterolemia, % 93.0 88.6 0.48
Diabetes mellitus
(treated with insulin)
7.0 11.4 0.48
Prior CVA/TIA, % 7.0 4.5 0.62
Previous MI, % 18.6 18.2 0.96
Previous PCI, % 46.5 36.4 0.34
Statin use, % 81.0 83.0 0.81
Beta-blocker use, % 70.0 75.0 0.90
ACE-I/ARB use, % 44.0 36.0 0.50
Creatinine, mg/dl 1.1  1.3 1.0  0.3 0.38
Coronary vessel
LAD 39.0 45.2 0.57
LCx 31.7 31.0 0.94
RCA 29.3 23.8 0.57
Values are mean  SD or %.
ACE-I ¼ angiotensin-converting enzyme inhibitor; ARB ¼ angiotensin receptor blocker; CVA ¼
cerebrovascular accident; LAD ¼ left anterior descending; LCx ¼ left circumﬂex; MI ¼ myocardial
infarction; PCI ¼ percutaneous coronary intervention; RCA ¼ right coronary Artery; TIA ¼ transient
ischemic attack.several studies have suggested statin-associated reduction in
lipid content in patients with nonobstructive coronary artery
disease (CAD) (17–19). Despite these observations, the extent
to which statins may modulate lipid content in severely
obstructive coronary lesions remains unknown. Furthermore,
possible changes in ﬂow physiology have never been studied.
Accordingly, we sought to determine the impact of intensive
statin therapy on the lipid content and ﬂow physiology in
patients with severely obstructive lesions, using diffuse reﬂec-
tance near-infrared spectroscopy (NIRS) (20) and fractional
ﬂow reserve (FFR) (21) in the prospective, randomized, single-
center, single-blinded YELLOW (Reduction in Yellow Pla-
que by Intensive Lipid Lowering Therapy) trial.
Methods
This prospective, randomized, single-center, single-blinded
trial included patients enrolled in the COLOR (Chemo-
metric Observation of Lipid Core Plaques of Interest in
Native Coronary Arteries) registry partially supported by
InfraReDx, Inc. (Burlington, Massachusetts), the company
that produces NIRS catheters. The institutional review
board approved the protocol. All patients provided written
informed consent. An independent data and safety moni-
toring board oversaw the conduct, safety, and efﬁcacy of the
trial. Imaging data analysis was performed by the Cardio-
vascular Research Foundation (New York, New York),
which had no knowledge of the clinical presentation of
patients, randomization to intensive versus standard inter-
vention, or the sequence (baseline or follow-up) of the
studies. Statistical analyses were performed by the data
coordinating center at the Cardiovascular Institute of Mount
Sinai Hospital (New York, New York), also unaware of
clinical data. InfraReDx Inc. played no role in the design,
analysis, interpretation, or presentation of this study.
Study population. From May 21, 2010, until January 10,
2012, 779 consecutive patients with chronic stable anginapresenting for elective coronary angiography were screened.
After clinical (n ¼ 108), angiographic (n ¼ 487), and other
(n ¼ 97) exclusion criteria (Online Fig. 1), 87 patients were
randomized to either intensive statin therapy with rosuvas-
tatin 40 mg daily (n ¼ 44) or standard therapy (n ¼ 43), as
shown in Figure 1. All patients enrolled in the YELLOW
trial underwent coronary angiography because of symptoms
of chronic stable angina (n ¼ 82) or without anginal
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23symptoms but positive stress test (n ¼ 5). There were no
signiﬁcant differences in demographic and clinical charac-
teristics, as shown in Table 1. Five patients were lost to
follow-up (2 in the intensive group and 3 in the standard
therapy group).
We excluded patients with acute myocardial infarction,
acute coronary syndromes, left main disease, liver disease,
serum creatinine >2.0 mg/dl, known hypersensitivity to sta-
tins, single-vessel or nonobstructive CAD, and lesions not
amenable to percutaneous coronary intervention (PCI).
Angiographic inclusion required at least 2-vessel obstructive
CAD, deﬁned as angiographic diameter stenosis >70%. The
target lesion was deﬁned using a correlation between the
vessel distribution containing the lesion and the area of
ischemia documented by nuclear stress testing. Segmental
changes documented at baseline electrocardiogram or during
left ventriculography also contributed to identifying the
target lesion. All target lesions were successfully treated with
coronary stenting. After successful PCI of the target lesion,
any remaining nontarget lesions with>70% diameter stenosis
were evaluated for hemodynamic signiﬁcance using FFR. If
the FFR was 0.8, the patient was enrolled in the study
and the lesion was further evaluated using gray-scale IVUS
and NIRS. No PCI was performed in this nontarget lesion.
Instead, patients were randomly allocated to rosuvastatin
40 mg daily þ optimal medical therapy or optimal medical
therapy alone, which included any clinically indicated statin
therapy that the patient was already taking. Blood samples
for lipid proﬁle, liver function, cardiac enzymes, and high-
sensitivity C-reactive protein were collected. After dis-
charge, all patients were contacted by phone 2 to 3 days later
and then once weekly. After 6 to 8 weeks, repeat angiography,
FFR, IVUS, andNIRS were performed at the same nontarget
lesion previously imaged. These repeated measurements were
performed before any additional PCI. Then, as indicated
clinically, successful PCI with coronary stenting was per-
formed immediately after in lesions with FFR 0.8. A ﬂow-
chart of the study design including the patients enrolled is
shown in Figure 1.
Angiographic analysis. All patients received intracoronary
nitrates before imaging. Angiographic analysis was per-
formed using 2 orthogonal projections. Lesion severity was
estimated visually and reported as percent diameter stenosis.
Obstructive lesions were deﬁned as angiographic stenosis
of >70%.
Fractional ﬂow reserve. FFR was measured with a coro-
nary pressure guidewire (St. Jude Medical, Minneapolis,
Minnesota or Volcano Corp., Rancho Cordova, California)
at maximal hyperemia induced by intravenous adenosine,
which was administered at a rate of 140 mg/kg of body weight
per minute through a central vein (21). If FFR conﬁrmed
hemodynamic signiﬁcance (0.80), the patient was enrolled,
and the lesion was imaged with IVUS and NIRS.
Intravascular ultrasound. IVUS was performed at baseline
and at follow-up using the Eagle Eye 20-MHz, 3.2-F
phased-array catheter (Volcano Corp.), as previouslydescribed (9). Image data were archived onto DVD and sent
to the Cardiovascular Research Foundation for ofﬂine
analysis using the validated planimetry software (EchoPla-
que, INDEC Systems, Inc., Mountain View, California). A
software transferring problem from the console to the
portable CD (sent to the imaging data analysis center)
precluded storage and analysis of all virtual histology data.
As such, no virtual histology was available for comparison.
Quantitative measurements were completed according to
criteria from the American College of Cardiology consensus
statement on IVUS (22).
Near-infrared spectroscopy. NIRS was performed at
baseline and at follow-up using a 3.2-F NIRS catheter
(InfraReDx, Inc.) using the ﬁrst-generation catheter
(without IVUS capabilities). The catheter was advanced into
the distal coronary artery and withdrawn by an automated
mechanical pullback at 0.5 mm/s and 240 rotations/min,
as previously reported (23). Spectroscopic information
obtained from raw spectra was transformed into a probability
of lipid core that was mapped to a red-to-yellow color scale,
with the low probability of lipid shown as red and the high
probability of lipid shown as yellow (24). Analyses were
performed ofﬂine using the Matlab-based software, as pre-
viously published (24). Yellow pixels within the analyzed
segment were divided by all viable pixels to generate the
lipid-core burden index (LCBI). The maximal value of
LCBI for each nonculprit obstructive lesion was recorded
and used for comparison. The primary endpoint for the
present study was the change in LCBI at the 4-mm maximal
segment (LCBI4mm max) before and after pharmacological
therapy.
Coregistration of IVUS, NIRS, and coronary angiography.
We performed coregistration by matching the angiographic,
IVUS, and NIRS data independently via landmark ﬁduciary
points and the position of the IVUS and NIRS imaging
catheter recorded on the coronary angiograms and accounting
for the pull-back speed on the IVUS and NIRS catheters.
The corresponding IVUS and NIRS segments were deter-
mined and compared at baseline and follow-up.
Statistical analysis. We hypothesized that rosuvastatin
40 mg daily would confer an approximate 35% reduction in
lipid-core content (17). Based on the distribution of LCBI
observed in a recent study (24), the present trial required
76 patients to detect a 35% reduction in LCBI with 80%
power. Assuming a 10% loss to follow-up, we enrolled an
additional 11 patients, for a ﬁnal sample size of 87 patients.
Clinical and demographic characteristics were compared
using a Student t test or chi-square test for continuous and
categorical variables, respectively. While LCBI 4-mm max
data displayed a normal distribution, corresponding lesion-
level data were highly skewed. Because LCBI data at the
lesion level were not normally distributed, comparisons
between and within groups were performed using non-
parametric tests. Differences between groups at each time
point were determined using a Wilcoxon rank-sum test,
whereas differences within groups at different time points
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24were assessed using the Wilcoxon signed-rank test. The
analogous comparisons in the absolute or percent change
between groups were performed using an independent
Student t test. The primary endpoint (change in LCBI4mm
max) was analyzed by analysis of covariance (ANCOVA)
performed on rank-transformed data with the baseline value
as a covariate. Ranking was performed on LCBI change
(staged minus baseline), and these rank-transformed values
were used as the dependent variable. Baseline LCBI was
included as a covariate after rank transformation. The initial
model was generated with change in LCBI4mm max (rank
transformed) as the dependent variable. This model included
treatment assignment and baseline LCBI4mm max (rank
transformed) as covariates. To assess consistency of treat-
ment effect, we repeated all analyses using lesion LCBI.
Because of differences in lesion length between groups, we
included lesion length as an additional covariate in lesion
analyses. Rank transformation of non-normally distributed
data is a valid approach when performing ANCOVA (25).Results
Biochemical, angiographic, FFR, and IVUS data. Base-
line and follow-up biochemical angiographic, FFR, and
IVUS parameters are shown in Table 2. Biochemical
parameters were well matched in both groups with the
exception of higher high-density lipoprotein levels in the
intensive group (p ¼ 0.04). Median (95% CI) follow-up in
the intensive therapy group (50 [49 to 56] days) was similar
to that in the standard therapy (49 [49 to 54] days) groupTable 2 Baseline and Follow-Up Chemical, Angiographic, and IVUS P
Baseline
Standard
(n ¼ 43)
Intensive
(n ¼ 44)
Cholesterol
Total, mg/dl 144.4  30.8 143.8  26.4
LDL-C, mg/dl 82.8  26.9 79.1  25.3
HDL-C, mg/dl 37.0  10.4 41.6  10.5
Non–HDL-C, mg/dl 107.4  30.3 102.2  25.3
LDL:HDL 2.1  0.9 1.9  0.6
Triglycerides, mg/dl 123.2  61.7 107.0  66.2
hs-CRP, mg/l 1.7 (0.7–3.4) 1.7 (0.8–3.5)
Angiography and FFR
Diameter stenosis, % 79.9 79.6
FFR 0.73  0.1 0.73  0.1
FFR change
Lesion length, mm* 34 (26–36) 42 (32–48)
IVUS
EEM volume, mm3 290  152 371  166
Attenuated plaques, % 21/43 (48.8) 31/44 (70.5)
TAV, mm3, normalized 197.3  61.7 195.8  63.3
Plaque burden % 75.6 75.9
Plaque þ media, mm2 8.2  3.5 8.4  3.7
Values are mean  SD, median (interquartile range), n/N (%), or %. *Lesion length measured using nea
CSA ¼ cross-sectional area; EEM ¼ external elastic membrane; FFR ¼ fractional ﬂow reserve; HDL-C ¼ h
ultrasound; LDL-C ¼ low-density lipoprotein cholesterol; TAV ¼ total atheroma volume.(p ¼ 0.53). At the end of follow-up, total cholesterol levels
in the intensive group were substantially lower (123.1  33.4
mg/dl) than in the standard group (148.6  34.5 mg/dl, p ¼
0.001). Similarly, low-density lipoprotein cholesterol levels
of 58.4  26.3 mg/dl in the intensive group was signiﬁcantly
lower compared with 81.9  27.9 mg/dl in the standard
group after treatment (p < 0.001). C-reactive protein levels
remained unchanged after therapy in either group. Percent
diameter stenosis by angiography and FFR ﬁndings were
similar in both groups (Table 2). FFR delta was similar in
the standard compared with the intensive group. Six patients
had improved FFR to >0.8 (2 in the standard and 4 in the
intensive groups). All 6 patients had signiﬁcant improve-
ment of symptoms; therefore, PCI was not performed.
However, this difference did not reach statistical signiﬁ-
cance. Baseline lesion length measured by NIRS was longer
in the intensive versus standard group (p ¼ 0.07). Baseline
IVUS demonstrated greater external elastic membrane
volume (p ¼ 0.05) and increased number of attenuated
plaques (p ¼ 0.04) in the intensive versus standard group.
Other gray-scale IVUS parameters were well balanced bet-
ween groups and are presented in Online Tables 1 to 3.
LCBI endpoints. Among 87 randomized participants,
paired baseline and staged LCBI measurements were not
available in 17 patients because of loss to follow-up (n ¼ 5),
incorrect image formatting that could not be recovered at the
time of core laboratory analysis (n ¼ 5), NIRS console/
catheter malfunction at the time of index PCI (n ¼ 3), and
loss of disc integrity or corruption before core laboratory
analysis (n ¼ 4). There were no differences in the frequencyarameters by Group
Follow-up
p Value
Standard
(n ¼ 43)
Intensive
(n ¼ 44) p Value
0.92 148.6  34.5 123.1  33.4 0.001
0.51 81.9  27.9 58.4  26.3 <0.001
0.04 38.4  12.0 42.5  10.2 0.09
0.39 110.2  33.6 80.6  31.5 <0.001
0.27 2.4  1.2 1.5  0.6 <0.001
0.25 138.7  90.6 108.9  69.4 0.09
0.84 1.9 (0.7–4.7) 1.2 (0.7–2.5) 0.17
0.89 83 79.4 0.08
0.95 0.73  0.1 0.75  0.1 0.36
0.01  0.08 0.02  0.07 0.49
0.07 34 (26–37) 39 (30–47) 0.13
0.05 300  155 404  271 0.07
0.04 20/43 (46.5) 30/44 (57.5) 0.04
0.93 199.6  63.9 209.6  74.1 0.57
0.86 74.9 75.3 0.83
0.89 8.0  3.5 8.6  4.2 0.53
r-infrared spectroscopy.
igh-density lipoprotein cholesterol; hs-CRP ¼ high-sensitivity C-reactive protein; IVUS ¼ intravascular
Table 3 Baseline, Follow-Up, and Change in Primary and Secondary LCBI Endpoints*
Standard
(n ¼ 34)
Intensive
(n ¼ 36) p Value
Baseline, median (IQR)
LCBI4mm max 356.7 (145.2 to 509.2) 490.6 (363.8 to 689.7) 0.01
LCBI, lesion 95.4 (29.6 to 174.6) 132.4 (99.0 to 201.2) 0.04
Follow-up, median (IQR)
LCBI4mm max 385.7 (139.2 to 510.9) 336.1 (252.3 to 479.9) 0.93
LCBI, lesion 99.9 (38.2 to 204.3) 99.8 (64.2 to 159.3) 0.88
Median change (95% CI)y
LCBI4mm max 2.4 (36.1 to 44.7) 149.1 (210.9 to 42.9) 0.01
LCBI, lesion 8.0 (7.7 to 22.1) 22.5 (59.2 to 3.5) 0.02
Median percent change (95% CI)
LCBI4mm max 0.6 (22.0 to 12.4) 32.2 (40.4 to 12.4) 0.02
LCBI, lesion 5.4 (19.6 to 34.1) 24.4 (43.6 to 2.0) 0.03
Any LCBI regression, %
LCBI4mm max 50.0 80.6 0.01
LCBI lesion 44.1 69.4 0.03
*Table includes LCBI comparisons for study participants with values at both baseline and staged time points (n ¼ 70). yp Values from analysis of
covariance models on rank-transformed data controlling for baseline LCBI. All conﬁdence intervals (CI) are distribution free.
IQR ¼ interquartile range; LCBI4mm max ¼ lipid-core burden index at the 4-mm maximal segment.
JACC Vol. 62, No. 1, 2013 Kini et al.
July 2, 2013:21–9 Lipid Atheroma and Statin Therapy: The YELLOW Trial
25of missing LCBI data between standard and intensive
groups (p ¼ 0.74). Baseline, follow-up, and absolute changes
in LCBI4mm max and lesion LCBI endpoints are shown in
Table 3 among those with complete LCBI data (n ¼ 70). At
baseline, the intensive group showed a higher LCBI4mm max
(p ¼ 0.01) and lesion LCBI (p ¼ 0.04) compared with the
standard group. At the end of follow-up, there were
signiﬁcant reductions in LCBI only in the intensive group.
Among those randomly allocated to intensive therapy,
LCBI4mm max decreased from 490.6 (363.8 to 689.7) at
baseline to 336.1 (252.3 to 479.9) at follow-up (p ¼ 0.01).
LCBI at the lesion was also reduced in the intensive group,
from 132.4 (99.0 to 201.2) at baseline to 99.8 (64.2 to
159.3) at follow-up (p ¼ 0.02). However, the standard
group showed no signiﬁcant changes after therapy. The
LCBI4mm max went from 356.7 (145.2 to 509.2) at baseline
to 385.7 (139.2 to 510.9) at follow-up (p ¼ NS), and the
LCBI at the lesion went from 95.4 (29.6 to 174.6) at
baseline to 99.9 (38.2 to 204.3) at follow-up (p ¼ NS). The
median percent change in LCBI4mm max segment after 7
weeks of intensive versus standard therapy was 32.2%
versus 0.6%, respectively (p ¼ 0.02). In addition, the
number of patients with any LCBI regression was higher in
the intensive group compared with the standard group at the
LCBI4mm max (80.6% vs. 50.0%; p ¼ 0.01) and at the lesion
LCBI (69.4% vs. 44.1%; p ¼ 0.03).
ANCOVA performed on rank-transformed LCBI data
demonstrated a signiﬁcant association between intensive
treatment and change in LCBI4mm max after adjustment for
rank-transformed baseline LCBI4mm max (F-test 8.24; p for
treatment effect ¼ 0.01) (Table 3). The association between
intensive treatment and change in LCBI at the lesion was
also signiﬁcant after adjustment for rank-transformed
baseline LCBI at the lesion (F-test 5.33; p for treatment
effect ¼ 0.02) (Table 3). Further adjustment for lesionlength in the lesion LCBI analyses did not alter the asso-
ciation between intensive treatment and change in lesion
LCBI (F-test 7.02; p for treatment effect ¼ 0.01).
Among the 70 patients with both baseline and follow-up
LCBI measurements, the location of the LCBI4mm max
at follow-up occurred at the identical anatomic site as
the baseline measurement in 53 patients. In the remaining
17 patients, the LCBI4mm max at follow-up occurred in a
different anatomic site of the lesion due to reductions in
LCBI at the original (baseline) site.
Accordingly, we performed additional sensitivity analyses
to evaluate consistency of treatment effect given that the site
of the LCBI4mm max was not identical at both time points
in all patients. First, we repeated the ANCOVA using the
LCBI4mm value at follow-up measured at the same anatomic
site as the LCBI4mm max measured at baseline. After
adjustment for baseline LCBI4mm (rank transformed), the
association between treatment assignment and change in
LCBI4mm (rank transformed) remained signiﬁcant (F-test
12.28; p for treatment effect ¼ 0.001).
In a second sensitivity analysis, we excluded those 17
patients in whom the follow-up LCBI4mm max measure-
ment occurred at a different anatomic site compared with
baseline. Results remained unchanged with our overall
ﬁndings (F-test 5.87; p for treatment effect ¼ 0.02).
Additional comparisons in LCBI measurements taken
during the study are presented in Online Tables 4 and 5.
FFR and relationship to LCBI. We performed additional
exploratory analyses to evaluate the associations between
change in FFR and LCBI. Among patients with any FFR
improvement (n ¼ 34), median reduction (95% conﬁdence
interval) in LCBI4mm max was signiﬁcantly greater
compared with patients with no FFR improvement (n ¼ 36)
(109.6 [203.2 to 23.5] vs. 22.3 [65.9 to 21.7]; p ¼
0.03), as seen in Figure 2A. Analogously, we found that the
Table 4 Clinical Events
Standard
(n ¼ 43)
Intensive
(n ¼ 44)
Death 0 (0.0) 0 (0.0)
Hospitalization for chest pain 2 (4.7) 3 (6.8)
Unplanned revascularization 2 (4.7) 0 (0.0)
Periprocedural complications 1 (2.3) 3 (6.8)
Any bleeding 2 (4.7) 0 (0.0)
AST >3 ULN 0 (0.0) 0 (0.0)
ALT >3 ULN 0 (0.0) 0 (0.0)
Creatine kinase-MB
>5 ULN 2 (5.6) 1 (2.9)
>10 ULN 2 (5.6) 0 (0.0)
Statin discontinuation 0 (0.0) 0 (0.0)
Statin dose reduction 0 (0.0) 3 (6.8)
Values are n (%).
ALT ¼ alanine aminotransferase; AST ¼ aspartate aminotransferase; ULN ¼ upper limit
of normal.
Figure 2
Comparison of Median Change (95% CI) in
LCBI4mm max Between Patients With FFR
Improvement (n ¼ 34) and Patients Without
FFR Improvement (n ¼ 36)
(A) Boxes represent mean reduction and lines indicate 95% conﬁdence interval
(CI). (B) Bar graph displaying a trend toward improvement in FFR across tertiles of
reductions in change in lipid-core burden index at the 4-mm maximal segment
(LCBI4mm max).
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26proportion of patients with any FFR improvement increased
in a stepwise fashion with the magnitude of LCBI4mm max
reduction, as seen in Figure 2B. No signiﬁcant changes were
observed in IVUS parameters between these groups (Online
Appendix).
Clinical events. The number of adverse events was low,
with no signiﬁcant differences between groups in any clinical
endpoints (Table 4). Two patients reported myalgias, treated
by lowering the dose of rosuvastatin to 20 mg/day. No cases
of liver abnormalities or rhabdomyolysis were observed.
There were no differences in periprocedural complications
or post-procedural creatine kinase MB elevation greater than
5 or 10 upper limit of normal. An example illustrating
angiography, FFR, IVUS, and NIRS of a patient in the
intensive group is shown in Figure 3.Subgroup analysis. The large reduction in LCBI4mm max
associated with intensive statin therapy observed in the
overall population remained consistent across numerous
subgroups, as seen in Figure 4.
Discussion
In this prospective, short-term, randomized YELLOW
trial, we quantiﬁed the effects of rosuvastatin to reduce lipid
content in severely obstructive coronary lesions compared
with standard therapy. Changes in lipid content were
quantiﬁed using NIRS (26). The median percent reductions
in LCBI4mm max in the intensive therapy and standard
groups were 32.2% and 0.6%, respectively (p ¼ 0.02).
Concordant, signiﬁcant changes were also observed in lesion
LCBI. These ﬁndings extend previous investigations using
different imaging modalities in nonobstructive lesions to
patients with severely obstructive CAD. Furthermore, the
results suggest that lipid-core content may regress rapidly
with intensive statin therapy in a short time period. Previous
intracoronary studies using IVUS in nonobstructive CAD
varied from 18 to 24 months of therapy (5,27,28). Although
gray-scale IVUS is an excellent tool to quantify atheroma
volume, it is not ideal to quantify lipid levels within coronary
atheroma. Furthermore, nonobstructive CAD is associated
with very slow disease progression and low clinical event
frequency, compared with patients with severely obstructive
CAD (29).
NIRS, the imaging modality that was used to quantify
lipid content in this study, has been extensively used to
identify the chemical content of biological specimens (30).
NIRS is based on the absorbance of light by organic
molecules. The reﬂectance spectra from wavelengths bet-
ween 400 and 2,400 nm allow detailed analysis of chemical
composition. NIRS can provide simultaneous, multicom-
ponent, nondestructive chemical analysis of biological tissue
with an acquisition time of <1 s (30). No sample prepara-
tion is required, and physical and biological properties can be
Figure 3 Examples of Angiography, FFR, IVUS, and NIRS in an Individual Case at Baseline and Follow-Up
(A) Baseline; (B) follow-up. Abbreviations as in Figures 1 and 2.
JACC Vol. 62, No. 1, 2013 Kini et al.
July 2, 2013:21–9 Lipid Atheroma and Statin Therapy: The YELLOW Trial
27derived from spectra. Previous correlations with histopa-
thology showed sensitivity and speciﬁcity of >90% for lipid
detection in human atheromas (31).
Results of the pilot YELLOW trial suggest changes in
plaque composition with short-term intensive statin therapy
in severely obstructive CAD. Previous randomized trials
successfully used high-dose statins in patients with acute
coronary syndrome and showed signiﬁcant improvements in
clinical events (32,33). This study, performed in patients
with stable angina, showed potential improvements in pla-
que physiology. Improvements in FFR (>0.8) were observed
in 6 patients (2 in the standard therapy group and 4 in the
intensive group), and patients with improvements in FFR
were characterized by a larger reduction in LCBI4mm max.
This preliminary observation suggests that short-term,
intensive reductions in LCBI may modulate coronary ﬂow
physiology, especially in plaques with large lipid cores. Given
the small sample size and post hoc nature of these com-
parisons; however, these observations exclusively in non-
culprit lesions with large lipid cores can only be considered
hypothesis generating and require prospective conﬁrmation.
Study limitations. The present study included a small
sample size and short duration of follow-up, reducing thepower to detect differences in clinically relevant endpoints. It
is also important to note that baseline LCBI was signiﬁ-
cantly higher in patients randomly allocated to intensive
versus standard therapy. Lack of baseline comparability in
randomized trials may occur because of chance and is more
likely to occur in smaller trials, such as ours (34,35). These
differences, therefore, were likely attributable to random
variation because clinical, demographic, and most of the
IVUS parameters were well balanced between groups at
baseline. In addition, results from the ANCOVA demon-
strated that the association between rosuvastatin therapy and
lipid-core reduction (LCBI4mm max and LCBI at the lesion)
persisted after accounting for baseline differences in LCBI.
It is plausible that the magnitude of LCBI reduction with
statin therapy may have been proportional to the burden of
atherosclerotic lipid content at baseline, as suggested by our
subgroup analyses in Figure 4. These analyses, however, are
post hoc exploratory comparisons and must be considered
hypothesis generating only. Given the inherent limitations
of subgroup analyses and our small sample size, larger
studies are needed to further clarify the association between
atherosclerotic lipid burden quantiﬁed by NIRS and plaque
modiﬁcation with statins. Finally, the modest association
Figure 4 Analysis Demonstrating Mean Change in LCBI4mm max by Clinical Subgroup
Boxes and lines represent mean change and 95% conﬁdence intervals, respectively. Interaction p values are from linear regression using change in LCBI4mm max as the
outcome variable. HDL-C ¼ high-density lipoprotein cholesterol; LDL-C ¼ low-density lipoprotein cholesterol; other abbreviation as in Figure 2.
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28between LCBI regression and improvement in FFR is
subject to the small sample size and short duration of
follow-up. We were unable to discern, therefore, whether or
not the observed changes in ﬂow dynamics were attributable
to reductions in lipid content alone or other salutary changes
in vessel physiology that might have occurred as a result of
lipid lowering. Larger studies with longer follow-up are
needed to conﬁrm and further elucidate the impact of
atherosclerotic lipid-core reduction on ﬂow physiology in
obstructive CAD. Another major limitation is delay in trial
registration until after completion.Conclusions
Short-term intensive statin therapy appears to reduce lipid
content in obstructive lesions, but the small sample size and
large baseline imbalances observed in this study reduce thereliability of these ﬁndings. Accordingly, these results should
be viewed as a hypothesis-generating pilot study, rather than
a deﬁnitive result.
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